The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
The review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant relapse. To reduce the hemato- logic toxicity is rec...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2014-07-01
|
| Series: | Opuholi Ženskoj Reproduktivnoj Sistemy |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/88 |
| id |
doaj-8259c53c6f7349f48488cdcb67078313 |
|---|---|
| record_format |
Article |
| spelling |
doaj-8259c53c6f7349f48488cdcb670783132021-07-29T08:46:47ZrusABV-pressOpuholi Ženskoj Reproduktivnoj Sistemy1994-40981999-86272014-07-010110211210.17650/1994-4098-2012-0-1-102-112103The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancerK. E. Borisov0Bashkirsky State Medical UniversityThe review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant relapse. To reduce the hemato- logic toxicity is recommended weekly injection of 4 mg/m2 in 1, 8, 15 days of a 28-day cycle of therapy, as its effectiveness is comparable to the effectiveness of the standard 5-day regime.https://ojrs.abvpress.ru/ojrs/article/view/88ovarian cancerrecurrenceplatinum-free intervaltopotecanweekly regimen |
| collection |
DOAJ |
| language |
Russian |
| format |
Article |
| sources |
DOAJ |
| author |
K. E. Borisov |
| spellingShingle |
K. E. Borisov The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer Opuholi Ženskoj Reproduktivnoj Sistemy ovarian cancer recurrence platinum-free interval topotecan weekly regimen |
| author_facet |
K. E. Borisov |
| author_sort |
K. E. Borisov |
| title |
The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer |
| title_short |
The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer |
| title_full |
The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer |
| title_fullStr |
The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer |
| title_full_unstemmed |
The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer |
| title_sort |
leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer |
| publisher |
ABV-press |
| series |
Opuholi Ženskoj Reproduktivnoj Sistemy |
| issn |
1994-4098 1999-8627 |
| publishDate |
2014-07-01 |
| description |
The review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant relapse. To reduce the hemato- logic toxicity is recommended weekly injection of 4 mg/m2 in 1, 8, 15 days of a 28-day cycle of therapy, as its effectiveness is comparable to the effectiveness of the standard 5-day regime. |
| topic |
ovarian cancer recurrence platinum-free interval topotecan weekly regimen |
| url |
https://ojrs.abvpress.ru/ojrs/article/view/88 |
| work_keys_str_mv |
AT keborisov theleadershipoftopotecaninthetreatmentofrecurrentplatinumresistantovariancancer AT keborisov leadershipoftopotecaninthetreatmentofrecurrentplatinumresistantovariancancer |
| _version_ |
1721251697372692480 |